Oregon Public Employees Retirement Fund grew its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 5.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,214 shares of the biopharmaceutical company’s stock after purchasing an additional 1,100 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Vanda Pharmaceuticals were worth $215,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in VNDA. Advisor Group Holdings Inc. acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at $28,000. Meeder Asset Management Inc. increased its holdings in shares of Vanda Pharmaceuticals by 79.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 5,661 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 2,502 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $73,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Vanda Pharmaceuticals by 147.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,575 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 5,699 shares during the period. Finally, Diversified Trust Co acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $99,000.

A number of equities analysts recently weighed in on the stock. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Saturday, October 31st. Smith Barney Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Thursday, October 29th. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 1st. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $14.86.

Shares of VNDA stock opened at $12.36 on Friday. The firm has a 50-day moving average price of $11.19 and a 200 day moving average price of $10.99. Vanda Pharmaceuticals Inc. has a twelve month low of $7.12 and a twelve month high of $17.85. The company has a market capitalization of $675.99 million, a price-to-earnings ratio of 5.91 and a beta of 0.48.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, October 28th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.03. Vanda Pharmaceuticals had a net margin of 47.31% and a return on equity of 27.43%. On average, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post 0.31 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia.

Read More: Stock Portfolio Tracker

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.